Silence Therapeutics plc (OTCMKTS:SLNCF) Short Interest Down 50.0% in March

Silence Therapeutics plc (OTCMKTS:SLNCF) was the target of a large drop in short interest during the month of March. As of March 31st, there was short interest totalling 100 shares, a drop of 50.0% from the March 15th total of 200 shares. Based on an average daily volume of 600 shares, the short-interest ratio is currently 0.2 days.

Silence Therapeutics Price Performance

OTCMKTS SLNCF traded up $0.45 during trading on Friday, reaching $0.95. 5,278 shares of the company’s stock were exchanged, compared to its average volume of 17,481. Silence Therapeutics has a fifty-two week low of $0.50 and a fifty-two week high of $14.75. The business has a 50 day moving average price of $1.25 and a 200-day moving average price of $2.81.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.